Učitavanje...
Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 after previous approval in Europe and other countr...
Spremljeno u:
| Izdano u: | Clin Kidney J |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295603/ https://ncbi.nlm.nih.gov/pubmed/30581563 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfy089 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|